Investor Watch | Neuron23 picks up $100M and a new Parkinson's disease candidate

Join The Conversation! | https://trialsitenews.com/
Neuron23, a biotech company focused on developing precision medicines for neurological and immunological diseases, has been receiving support from Westlake Village BioPartners and Kleiner Perkins for series A and B of drug development. However, as for the most recent round of funding, they got a huge boost from a reputable investor, the SoftBank Vision Fund.
The SoftBank Vision Fund, a sub-category of SoftBank Group Corp., invested a whopping 100 million dollars into the series C, accounting for nearly half of the 213.5 million in total financing. With this funding, the young biotech company now plans for a clinical trial by the end of the year.